<DOC>
	<DOC>NCT00856375</DOC>
	<brief_summary>This study will evaluate whether NKTR-102, an investigational drug has an anti-tumor effect in patients with colorectal cancer. This study will also evaluate how the safety and anti-tumor activity of NKTR-102 compares with irinotecan, a cancer drug that is approved for use in the US for treatment of patients with certain types of colorectal cancer.</brief_summary>
	<brief_title>NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Na√Øve, KRAS Mutant, Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>metastatic colorectal cancer tumor with kras mutation More than 1 prior regimen for treatment of metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Colorectal cancer, second line</keyword>
</DOC>